<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content
CDX

JIMT-1

Description

JIMT-1 (Breast Cancer CDX Model) 

The JIMT-1 breast cancer cell line was derived from a patient with ductal carcinoma. It is HER2-positive but resistant to trastuzumab, making it unique among breast cancer models. JIMT-1 is widely applied in resistance mechanism studies. Its biology reflects clinically relevant HER2-driven but refractory breast cancers. 

Key Features: 

  • Derived from ductal breast carcinoma. 
  • HER2-positive, trastuzumab-resistant. 
  • Aggressive xenograft growth. 
  • Represents therapy-resistant breast cancer. 

Applications: 
JIMT-1 is used to study resistance in HER2-positive breast cancer. Researchers test novel HER2-targeted and combination therapies with this model. It supports biomarker identification for therapy resistance. Its defined biology makes it critical in preclinical breast cancer pipelines. 

Details
Tumor Type
Breast
Tumor Subtype
Ductal Carcinoma
Organism
Human
Mouse Sex
Female
Mouse Strain
NOG
Mutated Genes
PIK3CA
Mutation: p.C420R
Effect: Missense Variant
Impact: Likely Pathogenic & Pathogenic
TP53
Mutation: p.R248W
Effect: Missense Variant
Impact: Pathogenic / Likely Pathogenic & Pathogenic & Uncertain Significance & Likely Pathogenic
Lumin Data
Proteomics
Expression Data
Growth Curve
View on Lumin